GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, the Company leverages its integrated development platform by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence and optogenetics.
GenSight's initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.
Market capitalization (24-Jul-2017)
Closing share price (24-Jul-2017)